Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBenchmark Holdings Regulatory News (BMK)

  • There is currently no data for BMK

Acquisition

2 Feb 2015 07:00

RNS Number : 6942D
Benchmark Holdings PLC
02 February 2015
 



 

 

2 February 2015

Benchmark Holdings plc

("Benchmark" or "the Company")

Acquisition of Improve International Limited

Benchmark Holdings Plc announces that it has acquired the entire issued share capital of Improve International Limited ("Improve"), the Swindon-based veterinary continuing professional development ("CPD") provider. Improve will sit within Benchmark's Technical Publishing division, which provides global knowledge transfer, technical insight, e-learning and market analysis for people and businesses working in agriculture, aquaculture and the food supply chain.

Improve organises CPD courses for veterinarians across the UK, Republic of Ireland, Scandinavia and mainland Europe from its bases in the UK and Portugal. The courses are run both privately and in conjunction with universities and other organisations. All of the courses are accredited by either ESVPS (The European School of Veterinary Postgraduate Studies) or Harper Adams University. Currently delivered primarily on a face-to-face basis; Benchmark's directors believe there is considerable scope for online development of the programmes in collaboration with their Technical Publishing division's digital arm.

The consideration for the acquisition comprises an initial payment of £3.2 million in cash and warrants to acquire 259,312 Benchmark ordinary shares at a price of £1.12 per share. The exercise of the warrants is conditional upon the extension of certain business contracts, and the warrants are expected to become exercisable in 2017. If they have not become exercisable and been exercised by 1 December 2017, the warrants will lapse. Additional consideration of up to £3.0 million in cash is payable under an earn-out by reference to achievement in the financial year ending 31 December 2015 of performance targets in excess of anticipated 2014 results.

Improve is being purchased from its three shareholders who comprise the senior management team; David Babington, Heber Alves and Rui Lobao, all of whom will remain with the business.

Improve generated £3.1 million* of revenue and £0.2 million* of earnings before taxation in the year ended 31 December 2013. Net assets at that date were £0.2 million*. Revenue for the year ended 31 December 2014 is expected to be £3.5 million** which represents revenue growth of 13% on 2013. Earnings before taxation for the year ended 31 December 2014 are expected to be £0.5m**.

This significant growth profile has been achieved through expansion across continental Europe - in particular Germany, Spain and Portugal - as well as new market developments in Mexico, USA and Australia and a significant new UK contract.

Improve is forecast to continue to grow both revenue and profit, and the acquisition is expected to be immediately earnings enhancing.

Malcolm Pye, Chief Executive of Benchmark Holdings Plc said:

"The acquisition of Improve will enable us to combine our digital and distance learning expertise with Improve's veterinary content across Europe, enhancing our ability to serve the professionals in our key veterinary markets. This is a significant step forward for our Technical Publishing division in both the food and companion animal markets. We plan to take Improve's successful face-to-face courses and deliver content digitally on an international basis."

* Unaudited aggregated financial statements** Management estimate of unaudited results

 

 

For further information, please contact:

 

 

Benchmark Holdings plc

Tel: 020 7920 3150

Malcolm Pye, CEO

 

Roland Bonney, COO

 

Rachel Aninakwah, Communications

 

 

 

Cenkos Securities PLC

Tel: 020 7397 8900

Ivonne Cantu / Liz Bowman, NOMAD

 

Russell Kerr, Sales

 

 

 

Tavistock Communications

Tel: 020 7920 3150

Matt Ridsdale / Niall Walsh / Keeley Clarke

 

 

Notes to Editors:

Founded in 2000, Benchmark represents a new model in sustainable business development. Over the last decade it has built a profitable group of companies on the economics of a sustainable food supply chain. The company is growing in response to a rapidly increasing demand for sustainable food supply chains, and in particular for seafood, from both mature and emerging markets.

Benchmark is an ethical company with an explicit policy based on the "3E's" definition of a sustainable business - ethics, environment and economics - which guides its strategy and operations.

Following the transformative acquisitions of SalmoBreed and Stofnfiskur in December 2014, the Group now has four divisions: Animal Health which researches, manufactures and markets medicines and vaccines particularly for aquaculture; Sustainability Science which researches and informs sustainable development in the food industry, Technical Publishing which effects technology transfer through online publishing and education, and Animal Breeding and Genetics which is the second largest supplier of salmon eggs and genetic expertise in the world. Benchmark operates internationally with offices in the UK, Ireland, Norway, USA, Brazil, China, Russia, Iceland, and Thailand and, as at 20 January 2015, employs 284 people.

For further information on Benchmark please visit www.bmkholdings.com.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQEAKAFELDSEFF
Date   Source Headline
17th Jan 20234:35 pmRNSPrice Monitoring Extension
11th Jan 20238:00 amRNSPosting of Notice of AGM
30th Dec 20227:00 amRNSTotal Voting Rights
16th Dec 20229:58 amRNSHolding(s) in Company
15th Dec 20227:00 amRNSFirst Day of Trading on Euronext Growth Oslo
14th Dec 20229:15 amRNSCompletion of private placement & retail offering
13th Dec 20224:30 pmRNSSufficient number of shares in VPS
6th Dec 20226:21 pmRNSSuccessful private placement and retail offering
6th Dec 20227:00 amRNSLast day of bookbuilding and application period
1st Dec 20223:36 pmRNSPublication of Annual Report and Notice of AGM
1st Dec 202210:58 amRNSStatus of bookbuilding
1st Dec 20227:00 amRNSProspectus & Commencement of Bookbuilding Period
30th Nov 202210:00 amRNSTotal Voting Rights
30th Nov 20227:01 amRNSPrivate Placing & Retail Offering
30th Nov 20227:00 amRNSQ4 Results
30th Nov 20227:00 amRNSFull Year Results
25th Nov 20227:00 amRNSNotice of Results
14th Nov 20224:40 pmRNSSecond Price Monitoring Extn
14th Nov 20224:35 pmRNSPrice Monitoring Extension
14th Nov 20224:35 pmRNSChange of Registered Office
31st Oct 20227:00 amRNSTotal Voting Rights
24th Oct 20227:00 amRNSTrading Update
19th Oct 20227:00 amRNSHolding(s) in Company
12th Oct 20224:41 pmRNSSecond Price Monitoring Extn
12th Oct 20224:35 pmRNSPrice Monitoring Extension
5th Oct 20224:35 pmRNSPrice Monitoring Extension
30th Sep 20227:00 amRNSTotal Voting Rights
21st Sep 20227:00 amRNSBlock listing Six Monthly Return
20th Sep 20227:00 amRNSBenchmark hosts Capital Markets Day today
16th Sep 20227:00 amRNSRefinances the Company's existing debt
15th Sep 20224:35 pmRNSPrice Monitoring Extension
6th Sep 20227:00 amRNSFixed Income Investor Meetings
31st Aug 20227:00 amRNSTotal Voting Rights
25th Aug 20227:00 amRNSQ3 Results
1st Aug 20227:00 amRNSNotice of Q3 Results
29th Jul 20227:00 amRNSTotal Voting Rights
14th Jul 20227:00 amRNSNotice of Capital Markets Day and Site Visit
1st Jul 202212:08 pmRNSHolding(s) in Company
30th Jun 20227:00 amRNSTotal Voting Rights
16th Jun 20224:41 pmRNSSecond Price Monitoring Extn
16th Jun 20224:36 pmRNSPrice Monitoring Extension
1st Jun 20227:00 amRNSConversion of loan into green loan
31st May 20227:00 amRNSTotal Voting Rights
23rd May 20225:15 pmRNSDirector Dealings
20th May 20221:05 pmRNSDirector Dealings
18th May 20227:00 amRNSSecond Quarter and Interim results
3rd May 20227:00 amRNSMarket Authorisation Update
29th Apr 20222:29 pmRNSTotal Voting Rights
28th Apr 20227:00 amRNSNotice of Q2 and Interim Results
21st Apr 20223:17 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.